Nuvation Bio Inc. (NYSE:NUVB) has been identified as one of the best high short interest stocks with significant upside potential. Truist increased its price target to $13 from $11, citing strong market uptake of Ibtrozi over competitors. RBC Capital also raised their target to $12 from $9 with an Outperform rating.

H.C. Wainwright recently lowered Nuvation Bio’s price target to $17 from $18 while maintaining a Buy rating. The company’s Q4 Ibtrozi net product revenue of approximately $15.7 million met expectations. Nuvation Bio is a clinical-stage biopharmaceutical company focused on oncology therapeutic candidates.

Despite NUVB’s investment potential, some believe other AI stocks offer greater upside with less risk. A report suggests looking into undervalued AI stocks that could benefit from Trump-era policies. For more insights on potential investment options, explore additional reports on stock doubling projections and hidden AI stocks.

Disclosure: None. This article was originally published by Insider Monkey.

Read more at Yahoo Finance: Truist Highlights Nuvation Bio’s (NUVB) Ibtrozi’s Robust Market Uptake and Lead Over Competitors